CompletedNot Applicable

Citicoline in Non-Arteritic Ischemic Optic Neuropathy

Italy40 participantsStarted 2017-02-20

Plain-language summary

The investigators tested the hypothesis whether the treatment with Citicoline in oral solution (OS-Citicoline) would increase or stabilize visual acuity, retinal ganglion cells (RGCs) function and neural conduction along the visual pathways (neuroenhancement), and/or induce preservation of RGCs fibers' loss (neuroprotection) in an human model of neurodegeneration: non-arteritic ischemic optic neuropathy (NAION).

Who can participate

Age range45 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Acute visual reduction episode from NAION occurring for more than 6 months
✓. Typical defects of the visual field evidenced with the Goldmann perimetry or with Humphrey perimetry 30-2
✓. Visual acuity not less than 1/10
✓. Having suspended any potential neuroprotective therapies (e.g., Coenzyme Q10) for at least 6 months.

What they're measuring

Change From Baseline in Visual Acuity at 9 Month

Timeframe: 9 months vs baseline

Trial details

NCT IDNCT03758118

SponsorFondazione G.B. Bietti, IRCCS

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-07-25

Results submitted2018-11-28

View on ClinicalTrials.gov More Non-arteritic Ischemic Optic Neuropathy trials